Biogen Idec grants Sunesis global rights to BTK inhibitor
Executive Summary
To expand its hematology business, cancer-focused Sunesis Pharmaceuticals Inc. received exclusive worldwide rights to Biogen Idec Inc.’s preclinical Bruton's tyrosine kinase (BTK) inhibitor SNS062.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice